Black Rock Inc. Alnylam Pharmaceuticals, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 9,547,663 shares of ALNY stock, worth $4.1 Billion. This represents 0.05% of its overall portfolio holdings.
Number of Shares
9,547,663
Previous 9,025,007
5.79%
Holding current value
$4.1 Billion
Previous $1.35 Billion
72.01%
% of portfolio
0.05%
Previous 0.03%
Shares
13 transactions
Others Institutions Holding ALNY
# of Institutions
742Shares Held
115MCall Options Held
588KPut Options Held
669K-
Capital World Investors Los Angeles, CA16.8MShares$7.22 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$5.72 Billion0.07% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.09 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.28MShares$1.84 Billion0.88% of portfolio
-
Dodge & Cox San Francisco, CA3.2MShares$1.37 Billion0.63% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $52.9B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...